tucatinib + trastuzumab + capecitabine + oxaliplatin

This regimen is a **four-drug combination** used in clinical trials and investigational settings primarily for the treatment of **HER2-positive metastatic or unresectable gastrointestinal cancers**, including colorectal cancer and gastric cancer. - **Tucatinib** is a small molecule **HER2 tyrosine kinase inhibitor** that blocks downstream signaling involved in cancer cell proliferation and survival. - **Trastuzumab** is a **monoclonal antibody** targeting the extracellular domain of **HER2**, leading to inhibition of HER2-mediated signaling and possible immune-mediated cytotoxic effects. - **Capecitabine** is a **prodrug of 5-fluorouracil (5-FU)**, a pyrimidine analog that inhibits thymidylate synthase and interferes with DNA synthesis. - **Oxaliplatin** is a **platinum-based chemotherapeutic** causing DNA crosslinking and apoptosis. This regimen is typically considered for patients with HER2-positive cancers who have received prior therapies or are participating in clinical research. It is **not standard care** but may be used in early-phase clinical trials[2][8].

Other names

tucatinib + trastuzumab + capecitabine + oxaliplatinTTC + oxaliplatinCAPOX + tucatinib + trastuzumab